The Effect Of Rosuvastatin Intensive Treatment On The Levels Of VEGF And HIF-1α In Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Objection:The incidence of coronary atherosclerotic heart disease(CHD)is increasing year by year, which cause serious damage to human health,Acute coronary syndrome(ACS) is one of the most severe type of CHD for its high fatality rate. Percutaneous coronary intervention(PCI) has been widely used in clinical to save patient’s life. Meanwhile,the myocardial injury caused by the PCI surgery has gradually been concerned. Vascular endothelial growth factor(VEGF)is one of the most important factors to promote new angiogenesis. It can promote angiogenesis ischemic tissues and improve endothelial damage. Hypoxia-inducible factor-1α(HIF-1α) is the most important factor for comprehensively adjusting hypoxia, fully participating in the body cells’ specific response for hypoxia. Many researches reported that the level of VEGF and HIF-1α in peripheral venous blood is much higher after PCI which has been proved to be associated with myocardial injury. In view of these researches above, we consider whether VEGF and HIF-1α can be used as acute myocardial injury markers after PCI, reflecting myocardial damage from the perspective of myocardial ischemia. Many studies have found that loading dose of a statin before PCI surgery contributes to protection from myocardial ischemic injury. Rosuvastatin is the new member of statins which has good curative effects、low side effects and more and more recognition. Several studies suggested that intensive treatment with statins(20-40 mg befor PCI)may reduce myocardial damage caused by PCI.This research focus on exploring the effect of Rosuvastatin intensive treatment on the levels of VEGF and HIF-1α in coronary arterial blood of patients with ACS undergoing PCI.Methods: Fifty-nine patients with ACS undergoing elective PCI surgery were randomly divided into intensive conventional treatment group of 29 case(only to give conventional treatment of Rosuvastatin 10 mg once every night,8 hours before surgery not administered)and intensive treatment group of 30cases(8 hours before surgery to give Rosuvastatin 20 mg on the basis of conventional treatment of Rosuvastatin).The two groups’ coronary arterial blood were collected before the surgery and 1 hour after the first time of balloon dilatation, the detection level of VEGF and HIF-1α were compared.Results: 1 The levels of VEGF and HIF-1α before PCI surgery were not significantly different between the conventional treatment group and intensive treatment group(P >0.05); 2 Levels of VEGF and HIF-1α were much more higher after PCI surgery in both the two groups, the difference was statistically significant.(P<0.05); 3 The elevated extent of VEGF and HIF-1α after PCI in intensive treatment group was lower than the conventional treatment group, the difference was statistically significant.(P<0.05).Conclusions: 1 PCI surgery causes myocardial injury and ischemia, increasing the secretion of VEGF and HIF-1α,which could be the new maker of early myocardial ischemia. 2 Giving patient the intensive therapy of Rosuvastatin before PCI surgery could lower the VEGF and HIF-1α level after the surgery. 3 For the ACS patients who have accepted regular Rosuvastatin treatment, giving intensive treatment of Rosuvastatin(20mg before PCI)could reduce the myocardial damage caused by PCI surgery.